Incyte | INCY - Gross Profit On Sales


Incyte reported $1.17B in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Agenus USD 34.2M 4.61M Dec/2025
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Amgen USD 6.89B 415M Dec/2025
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Exelixis USD 590.86M 18.68M Mar/2026
Gilead Sciences USD 5.52B 791M Mar/2026
Incyte USD 1.17B 217.51M Mar/2026
Ionis Pharmaceuticals USD 243M 48M Mar/2026
MacroGenics USD 31.11M 30.14M Dec/2025
Merck USD 10.85B 2.57B Dec/2025
Moderna USD -566M 792M Mar/2026
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 10.07B 184M Mar/2026
Novartis USD 10.82B 694M Sep/2025
Pfizer USD 11.04B 1.24B Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026